Scientists Warn of “Cicada” COVID Variant’s Alarming Resurgence After Years of Silence
Just as global health experts believed we’d moved past the age of unpredictable COVID mutations, a concerning new strain has surfaced with a name that reflects its unsettling behavior: “Cicada.” Officially labeled BA.3.2, this variant is now sparking urgent discussions among virologists and public health authorities as it rapidly appears across multiple nations, including at least 25 U.S. states.
The “Cicada” moniker originates from the variant’s unusual dormancy pattern—mirroring the insect that spends years underground before suddenly reappearing in massive numbers. BA.3.2 was initially detected in South Africa in late 2024 but remained virtually invisible for nearly two years, circulating at such minimal levels that global tracking systems barely registered its existence. However, early 2026 saw an abrupt explosion of cases across Europe and North America, catching many by surprise.
What troubles researchers like Dr. Andrew Pekosz of Johns Hopkins is the variant’s genetic profile. BA.3.2 boasts an alarming 70 to 75 mutations in its spike protein—the component responsible for infiltrating human cells. This represents the most dramatic genetic shift since the original Omicron outbreak, making the Cicada variant appear drastically different to our immune defenses compared to the JN.1 and LP.8.1 strains targeted by current vaccines.
Early lab results indicate that BA.3.2 excels at evading immunity. Studies from the CDC and international labs reveal that antibodies from prior infections or recent boosters struggle to neutralize this strain effectively. In regions like Denmark and Germany, the variant already accounts for 30% of sequenced cases, suggesting it may outcompete other strains in populations with existing immunity.
Yet there’s a silver lining: while BA.3.2 slips past some immune defenses, there’s no evidence it causes more severe illness or higher death rates. Reported symptoms align with recent Omicron variants—intense sore throat, fatigue, congestion, and cough—with some patients noting increased night sweats. Notably, loss of taste or smell remains uncommon.
Experts stress that while vaccines may offer reduced protection against infection, they still significantly curb hospitalizations and deaths. Our T-cells—the immune system’s frontline defenders—retain enough recognition of the virus to prevent critical illness in most cases.
As of late March 2026, the Cicada variant represents a small percentage of U.S. cases, but wastewater data from Hawaii to New York hints at faster spread than clinical testing reveals. Whether it triggers a summer wave or lingers as a minor threat hinges on its evolution. For now, health officials advocate “cautious awareness.” The Cicada has awakened, serving as a stark reminder that COVID continues to adapt—and we must stay prepared.
